Page 227 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Optimal timing and response criteria of Interim-PET in DLBCL
20. Schöder H, Polley MC, Knopp MV, et al. Prognostic value of interim FDG-PET in diffuse large cell
lymphoma: results from the CALGB 50303 clinical trial. Blood. 2020;135(25):2224-2234.
21. Rekowski J, Hüttmann A, Schmitz C, et al. Interim PET evaluation in diffuse large B-cell lymphoma using published recommendations: Comparison of the Deauville 5-point scale and the DSUV max method. J Nucl Med. 2021;62(1):37-42.
22. Györke T, Carr R, Cerci JJ, et al. Combined visual and semiquantitative evaluation improves outcome prediction by early mid-treatment 18 F-FDG PET in diffuse large B-cell lymphoma. J Nucl Med. 2020;61(7):999-1005.
23. Nyilas R, Farkas B, Bicsko RR, et al. Interim PET/CT in diffuse large B-cell lymphoma may facilitate identification of good-prognosis patients among IPI-stratified patients. Int J Hematol. 2019;110(3):331-339.
24. Kurch L, Andreas H, Georgi TW, et al. Interim positron emission tomography in diffuse large B-cell lymphoma. J Nucl Med. 2020;jnumed.120.255034.
25. Poeschel V, Held G, Ziepert M, et al; German Lymphoma Alliance. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019; 394(10216):2271-2281.
26. Persky DO, Li H, Stephens DM, et al. Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol. 2020;38(26):3003-3011.
27. Maurer MJ, Habermann TM, Shi Q, et al. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol. 2018;29(8):1822-1827.
28. Schmitz C, Hüttmann A, Müller SP, et al. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: post-hoc analysis from the PETAL trial. Eur J Cancer. 2020;124:25-36.
29. Barrington SF, Meignan M. Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden. J Nucl Med. 2019;60(8):1096-1102.
30. Cottereau AS, Nioche C, Dirand AS, et al. 18F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome. J Nucl Med. 2020;61(1):40-45.
225
8